Annovis Bio, Inc. (ANVS) stock profile

Frequently asked questions

What does Annovis Bio, Inc. (ANVS) do?

Annovis Bio, Inc., a clinical-stage drug platform company, develops drugs to treat neurodegeneration. Its lead compound is Buntanetap, an orally administered drug that has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, and is also in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. The company is also developing ANVS405 for protecting against traumatic brain injury and stroke, and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. Annovis Bio was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Where is ANVS stock listed?

Annovis Bio, Inc. trades under the ticker ANVS on NYSE.

How can I research ANVS's financials and filings?

Vantafin provides Annovis Bio, Inc.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the ANVS profile.